Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beam Therapeutics (BEAM) Net Income towards Common Stockholders (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Net Income towards Common Stockholders for 7 consecutive years, with $244.3 million as the latest value for Q4 2025.

  • Quarterly Net Income towards Common Stockholders rose 370.38% to $244.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$80.0 million through Dec 2025, up 78.77% year-over-year, with the annual reading at -$80.0 million for FY2025, 78.77% up from the prior year.
  • Net Income towards Common Stockholders for Q4 2025 was $244.3 million at Beam Therapeutics, up from -$112.7 million in the prior quarter.
  • The five-year high for Net Income towards Common Stockholders was $244.3 million in Q4 2025, with the low at -$201.6 million in Q1 2021.
  • Average Net Income towards Common Stockholders over 5 years is -$62.4 million, with a median of -$90.7 million recorded in 2024.
  • The sharpest move saw Net Income towards Common Stockholders crashed 535.13% in 2021, then surged 472.36% in 2023.
  • Over 5 years, Net Income towards Common Stockholders stood at -$64.7 million in 2021, then skyrocketed by 40.73% to -$38.3 million in 2022, then soared by 472.36% to $142.8 million in 2023, then plummeted by 163.27% to -$90.4 million in 2024, then skyrocketed by 370.38% to $244.3 million in 2025.
  • According to Business Quant data, Net Income towards Common Stockholders over the past three periods came in at $244.3 million, -$112.7 million, and -$102.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.